US FDA Review Of Akebia’s Vafseo Informed By Roxadustat, Daprodustat Safety Concerns
Executive Summary
Vadadustat's review overlapped with two other oral HIF-PH class drugs. Safety issues with FibroGen/AstraZeneca’s roxadustat drew attention during vadadustat's first-cycle review, while GSK’s Jesduvroq labeling and postmarketing requirements informed the second-cycle approval.